Glutamine synthetase (EC 6.3.1.2, also known as -glutamyl:ammonia ligase) catalyzes the ATP-dependent condensation of glutamate and ammonia to form glutamine. The enzyme has essential roles in different tissues and species, which has led to its consideration as a drug or herbicide target. In the present paper, we describe studies aimed at the discovery of new antimicrobial agents targeting Mycobacterium tuberculosis, the causative pathogen of tuberculosis. A number of distinct classes of glutamine synthetase inhibitors with IC 50 s µM or better were identified via high-throughput screening. A commercially available purine analogue similar to one of the clusters identified (the diketopurines), 1-[(3,4-dichlorophenyl)-methyl]-3,7-dimethyl-8-morpholin-4-yl-purine-2,6-dione, was also shown to inhibit the enzyme, with a measured IC 50 of 2.8 ± 0.4 µM. Two X-ray structures are presented. One is a complex of the enzyme with the purine analogue alone (2.55 Å resolution), and the other includes the compound together with methionine sulfoximine phosphate, magnesium and phosphate (2.2 Å resolution).
Introduction
Long thought to be a disease that was "under control", tuberculosis has reemerged as an even greater global threat. Much of the problem arises from the lengthy (~6 months), and often unpleasant, regimen of drugs needed for a cure, and the drug resistance that results from poor patient compliance. The prognosis for a patient diagnosed with multi-drug resistant tuberculosis is at present worse than for one diagnosed with AIDS, and the situation is expected to worsen in the future. Clearly, new and better drugs are needed.
Glutamine synthetase (GS; EC 6.3.1.2, also known as -glutamyl:ammonia ligase) catalyzes the ATP-dependent condensation of glutamate and ammonia to form glutamine. The role of GS in humans depends on the tissue localization. In the brain it regulates the levels of toxic ammonia and converts neurotoxic glutamate to harmless glutamine, while in the liver GS is one of the enzymes responsible for the removal of ammonia. In bacteria and plants, the enzyme is responsible for fixation and re-assimilation of ammonia, allowing glutamine to be used as a nitrogen source for metabolism. Glutamate is also one of the most important charged compounds used by bacteria for osmoregulation. Further, poly-glutamine/glutamate is a key cell wall component and virulence factor of mycobacterial pathogens, accounting for as much as 10% of the dry weight of the cell wall. [1] [2] [3] GS action has additionally been proposed to prevent the acidification of phagosomes that is required for their fusion with lysosomes, so allowing the mycobacteria to avoid destruction by the macrophages. 4, 5 Of the four genes encoding GSs in M. tuberculosis, only one, glnA1 (hereafter assumed to encode MtGS), was found to be essential for in vivo survival of the bacteria. 3 Methionine sulfoximine (MSO) arrests the growth of bacteria by inhibiting extracellular MtGS, 6 and caused up to one log reduction of colony-forming units in guinea pigs infected with M. tuberculosis; its action was synergistic with isoniazid, a current frontline drug. 7 The structure of MtGS bound to phosphorylated MSO (MSO-P), metals and ADP was reported earlier. 8 Here we used high-throughput screening to identify novel compounds that inhibit MtGS efficiently. Kinetic studies, as well as X-ray structures of one inhibitor (PA, 1-[(3,4-dichlorophenyl)methyl]-3,7-dimethyl-8-morpholin-4-yl-purine-2,6-dione, see Figure 1 (a)) bound to GS show that, in contrast to previously known inhibitors such as MSO and phosphinothricin, which are glutamate-like, the new compounds enter the nucleotide-binding site. As this site is very different in the enzymes from the two species, it offers better prospects for selective binding
to MtGS compared to the human enzyme. Both the high-throughput screening and the structures pave the way for the design of improved inhibitors. As part of this work, we also devised a novel, straightforward synthesis of L-(SR)-methionine sulfoximine phosphate (L-(SR)-MSO-P, Figure   1 (b)), which will provide a useful tool for further work with GSs.
Results
Kinetic parameters--The measured K m for glutamic acid was 21.6 3.4 mM, and those for ATP and ammonium chloride were 0.50 0.06 mM and 10.8 0.6 mM, respectively, under the conditions of the assay used for screening. The optimal MgCl 2 concentration was ~25 mM; higher concentrations led to inhibition. The pH optimum was near 7.5, with HEPES as the best buffer tested. DMSO gave a slight (~15%) activation at a concentration of 2%.
High-throughput screening--To optimize the detection of inhibitor binding, assay conditions (30 mM glutamic acid, 1 mM ATP, 10 mM ammonium chloride, 25 mM MgCl 2 ) were chosen to be near the K m values for glutamate, ATP and ammonium. Of the 75,000 compounds entering the primary screen, 836 were found to be "actives" using a criterion of 30% inhibition at a 30-M concentration. Of these, 120 had measured IC 50 s better than 30 M. Seventy-five gave satisfactory results in a protein concentration response (to test for possible promiscuity), and so qualified for further work. The inhibitory activity of these compounds was confirmed in an orthogonal assay where the formation of glutamine was measured; 2 of the compounds failed at this point. The 73 remaining compounds were assigned to 11 clusters. These clusters were
enriched from the corporate library using near-neighbor analysis, to generate a refined library of 1100 compounds. All of these were rechecked for dose response. In addition, it was demonstrated that the compounds obtained were competing with ATP in the assays. PA inhibition --Substructure searches in databases of commercially available compounds were performed on several of the above clusters, with the purpose of identifying compounds that could be rapidly acquired for X-ray crystallographic studies. Based on these searches, the PA inhibitor ( Figure 1 (a)) belonging to cluster 10 was identified. Under conditions very similar to those used for high-throughput screening, the measured IC 50 of MtGS for this compound was 2.5 ± 0.4 µM.
Equivalent tests for the human enzyme (prepared as described previously 9 ) resulted in an IC 50 of 146 ± 24 µM.
Synthesis of L-(SR)-MSO-P--
The synthetic procedure used to prepare the L-(SR)-MSO-P diastereomers from L-(SR)-MSO is described in Figure 2 . The amino and carboxylic functions of L-(SR)-MSO were protected in two steps with carbobenzyloxy and benzyl moieties, respectively.
Phosphorylation of the diprotected sulfoximine 2 was carried out with o-xylylene N,Ndiethylphosphoramidite according to the procedure reported by Tokutake et al. 10 In the phosphorylation step we did not directly obtain structure 3, but an intermediate hydroxymethyl 
and L-(RR)-3''). We assign the structure of 3'' as depicted in Figure 2 and suggest that compound 3' might exist in equilibrium with 3''. Addition of aqueous tert-butyl hydroperoxide to the reaction mixture gave the desired N-phosphoryl sulfoximine 3 in 51% yield. Hydrogenation of compound 3 at 
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MtGS/PA structure--The structure of MtGS bound to PA was solved at 2.55 Å resolution, using the dodecamer from an earlier MtGS apo structure 13 in molecular replacement. Residues 4-478
were observed for each of the 12 chains in the asymmetric unit, with the exception of residues 63-66 and 405-412; these last were omitted from the model, as the density of the cyclically averaged maps did not allow them to be placed with confidence. Density for residues 58-59 and 334-335
was also very weak. The subunits were restrained using non-crystallographic symmetry (NCS) during the refinement, and with the exception of the loops mentioned above as having poor/weak density, no appreciable differences between them were apparent.
The twelve active sites of the dodecamer are found in long grooves between the subunits.
Each site contains clear electron density for the inhibitor. , and the added magnesium ions, electron density is seen for a phosphate ion. When the MSO-P sample alone was tested in the assay, phosphate contamination (~5%) was evident, which could arise either from hydrolysis or as an impurity of MSO-P. Since the nitrogen-phosphorus linkage is reported to be highly stable, 11 we presume that the latter is the case. Density is also observed for a molecule of PEG, which has no apparent structural or functional significance.
Comparison to MtGS/PA indicates that 368 C atoms match within a 3. This side chain instead interacts with Glu227 and a water coordinating the n3 metal. The difference is due to the presence of the metal, and the strand shift. and reflect small (<1 Å) movements that accommodate the dichlorophenyl group of the inhibitor.
Comparisons to previous MtGS structures--Comparison

Discussion
Selectivity is a vital consideration in the design of a new drug candidate. Comparison of the active sites of mammalian and mycobacterial GSs earlier 9 indicated that the nucleotide-binding site offered the best hope for obtaining a compound that would inhibit MtGS, but have no effect on human GS. Therefore, compounds were tested in an assay suited to obtaining inhibitors that bind in this site. High-throughput screening was performed using a 75,000-compound library carefully chosen to represent all of the classes of compounds present in the AstraZeneca corporate library; the screened library also contained a number of kinase inhibitors, to further bias the search toward the ATP site. In this way, a number of compounds were identified with IC 50 s in the range of nM to M; these were furthermore shown to compete with ATP. A commercially available compound (PA) was also found that is similar to one of the clusters identified (cluster 10, the diketopurines), and investigated further. The PA compound was found to have an IC 50 of 2.5 ± 0.4 µM.
The crystal structure of an enzyme-inhibitor complex is a powerful tool for designing improved compounds during lead optimization studies. Thus the structure was solved for MtGS in the presence of the PA inhibitor, which showed that binding did indeed occur in the nucleotide site. However, the MtGS/PA structure is a relaxed low pH, metal-free conformation that is not active. It was therefore unclear whether the observed mode of PA binding would correspond to that most important under in vivo conditions. In addition, crystallization was not reproducible, and the resolution observed for the ~100 crystals, and more than 1000 conditions, tested was not as good as one would like for a systematic analysis of other inhibitors. Crystals of the taut (active) conformation seen in the MtGS/MSO-P/MgADP structure 8 were obtained much more reproducibly, and diffracted to higher resolution. The numerous interactions with glutamate, phosphate, and metals are key to stabilizing this form of the protein in vivo. However, despite extensive trials including glutamate, etc, we were unable to identify conditions that resulted in a taut conformation in the presence of PA. It was believed that including MSO-P in the crystallization experiments would be advantageous, since the phosphorylated inhibitor binds much more tightly than the substrate glutamate. As MSO-P is not commercially available, it was generated in situ for the previous structure; the protein was incubated with MSO and ATP prior to crystallization, so producing MSO-P and ADP. However, displacement of ADP with PA proved prohibitively slow.
Synthesis and isolation of L-(SR)-MSO-P proved to be the solution to the problem. The
MtGS/MSO-P/MgPi/PA structure represents the taut conformation, and both reproducibility of the crystallization and the resulting resolution were substantially improved. Although the preparation contained a mixture of S and R forms at the sulfur center, the species bound to MtGS was the active S form.
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Comparison of the structures of MtGS/PA complexes with and without MSO-P indicated that the inhibitor bound in the same site, and in a very similar way. Minor differences were attributable to metal binding, and to the -strand shift that characterizes the relaxed/taut transition. Thus, it is expected that the PA compound will inhibit MtGS, regardless of its conformational state in vivo. Further, MSO-P is a generally important tool for crystallization of inhibitors bound to the nucleotide site, which should allow the solution of further structures. A straightforward synthesis of the compound is therefore of wider value, for our and other GS studies.
That nucleotide site-based MtGS inhibitors can reasonably be expected to discriminate strongly against human GS is illustrated in Figure 5 Combined, these structures provide a good starting point for designing inhibitors that will bind even more tightly. An example of such an improvement would be the introduction of new interactions with Glu214, which lies near the morpholino group of the present compound. This and other approaches will be pursued in future studies. One important goal will be to seek compounds that are taken up effectively by macrophages as well as by the bacteria, since compounds that exhibit bacteriocidal effects extracellularly and on phagocytized M. tuberculosis may stand the best chance of performing well as anti-mycobacterial drugs.
Materials and Methods
Chemicals--All restriction enzymes were purchased from Boeringer Manheim, Germany/Bangalore Genei, India. Plasmid pTrc99c was bought from Invitrogen (USA).
Monosodium glutamate and glutamine were obtained from Sigma-Aldrich Co. (USA), and PA from InterBioScreen (Moscow, Russia). The piColorlock Gold reagent kit was purchased from Innova Biosciences (UK). Microtiter plates used for screening were from Greiner. The HPLC C18 column was purchased from Waters (USA). The Ni-NTA column (Qiagen) was used for the isolation of His-tagged recombinant MtGS. The molecular weight of the protein was determined using mass spectrometer VG-Quatro (Manchester, England). Tips and plates were purchased from Beckman (USA).
Protein expression and purification--Escherichia coli strain GJ4745, lacking adenylyltransferase,
was the kind gift of Dr. Gowrishankar, Center for Cellular and Molecular Biology, Hyderabad, India. Protein for structural studies was over-expressed and purified in this strain, using methods described previously. 8 For high-throughput screening, the glnA1 gene from the same construct was subcloned into pTrc99c using the XbaI and Hind III sites, and protein was expressed in the GJ4745 strain. Recombinant MtGS obtained in this way was shown to be completely unadenylylated by mass spectrometry, and so fully active. PA kinetic studies--Assays and IC 50 determination for PA were performed under the conditions described for high-throughput screening, with the small difference that the ammonium chloride concentration was 30 mM, and the final reaction volume was 100 l. The incubation was carried out for 1 h at room temperature, after which inorganic phosphate was detected using a PiColorlock Gold reagent kit. Table 1 .
Assays and library screening--The
Synthesis of L-(SR)-MSO-P--
Crystals of the MtGS/MSO-P/MgPi/PA complex appeared under conditions similar to those used for the MtGS/MSO-P/MgADP complex earlier. 8 The MtGS hexamer from PDB entry 2BVC (water molecules and ligands removed) was used directly; rigid-body refinement was followed by rounds of refinement with NCS restraints. In the final round of refinement, NCS was tightly restrained for residues 3-402 and 417-478 (as well as associated waters and other ligands) of chains B-F to their equivalents in chain A, to allow for differences at residues 403-416. Water molecules were added in averaged |F o |-|F c | maps.
Geometric analysis using MolProbity indicated that 98.8 % of residues were in the most-favored Ramachandran regions, and there were no Ramachandran outliers. Other statistics for data collection and refinement are summarized in Table 1 .
Other methods--Structures were compared using the programs LSQMAN 19 
Accession numbers
The atomic coordinates and structure factors have been deposited at the Protein Data Bank, www.pdb.org (PDB ID codes 2WHI and 2WGS for the structures with and without MSO-P, respectively). 
